Key result
Methicillin-resistant Staphylococcus aureus infective endocarditis was not associated with significantly higher mortality compared to methicillin-susceptible strains (49.7% vs. 43.1%, p=0.32).
Why the study?
Staphylococcus aureus infective endocarditis has high mortality, and differences between MRSA and MSSA cases alongside prognostic factors required analysis.
Does methicillin resistance worsen prognosis or one-year mortality in patients with Staphylococcus aureus infective endocarditis?
Cohort (n=437)
Yes
Does methicillin resistance worsen prognosis or one-year mortality in patients with Staphylococcus aureus infective endocarditis?
Absolute Event Rate: 49.7% vs 43.1%
p-value: p=0.32
In patients with S. aureus infective endocarditis, methicillin resistance is associated with specific clinical factors like COPD and prior invasive procedures but does not significantly increase one-year mortality compared to methicillin-susceptible strains.
BACKGROUND: S. aureus (SA) infective endocarditis (IE) has a very high mortality, attributed to the age and comorbidities of patients, inadequate or delayed antibiotic treatment, and methicillin resistance, among other causes. The main study objective was to analyze epidemiological and clinical differences between IE by methicillin-resistant versus methicillin-susceptible SA (MRSA vs. MSSA) and to examine prognostic factors for SA endocarditis, including methicillin resistance and vancomycin minimum inhibitory concentration (MIC) values > 1 μg/mL to MRSA. METHODS: Patients with SA endocarditis were consecutively and prospectively recruited from the Andalusia endocarditis cohort between 1984 and January 2017. RESULTS: We studied 437 patients with SA endocarditis, which was MRSA in 13.5% of cases. A greater likelihood of history of COPD (OR 3.19; 95% CI 1.41-7.23), invasive procedures, or recognized infection focus in the 3 months before IE onset (OR 2.9; 95% CI 1.14-7.65) and of diagnostic delay (OR 3.94; 95% CI 1.64-9.5) was observed in patients with MRSA versus MSSA endocarditis. The one-year mortality rate due to SA endocarditis was 44.3% and associated with decade of endocarditis onset (1985-1999) (OR 8.391; 95% CI (2.82-24.9); 2000-2009 (OR 6.4; 95% CI 2.92-14.06); active neoplasm (OR 6.63; 95% CI 1.7-25.5) and sepsis (OR 2.28; 95% CI 1.053-4.9). Methicillin resistance was not associated with higher IE-related mortality (49.7 vs. 43.1%; p = 0.32). CONCLUSION: MRSA IE is associated with COPD, previous invasive procedure or recognized infection focus, and nosocomial or healthcare-related origin. Methicillin resistance does not appear to be a decisive prognostic factor for SA IE.
No takes yet. Share an insight, caveat, or question.
Hidalgo‐Tenorio et al. (2020) conducted a cohort in Staphylococcus aureus infective endocarditis (n=437). Methicillin-resistant Staphylococcus aureus (MRSA) vs. Methicillin-susceptible Staphylococcus aureus (MSSA) was evaluated on Infective endocarditis-related mortality (p=0.32). Methicillin-resistant Staphylococcus aureus infective endocarditis was not associated with significantly higher mortality compared to methicillin-susceptible strains (49.7% vs. 43.1%, p=0.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: